Table 1.
Baseline | Exercise (control) | Inflation (nadir) | Inflation (steady state) | Deflation (acute) | Deflation (steady state) | |
---|---|---|---|---|---|---|
20% MVC (NO DRUG) | ||||||
FBF (ml min−1) | 95 ± 25 | 468 ± 33* | 298 ± 31*† | 436 ± 37*‡ | 509 ± 43*‡§ | 501 ± 37*‡§ |
FVC [ml min−1 (100 mmHg)−1] | 107 ± 27 | 520 ± 42* | 385 ± 28*† | 510 ± 44*‡ | 558 ± 56*‡ | 558 ± 47*‡ |
20% MVC (PHENTOLAMINE) | ||||||
FBF (ml min−1) | 328 ± 36a | 657 ± 70*a | 383 ± 49†b | 642 ± 70*‡a | 755 ± 88*‡§a | 685 ± 75*‡a |
FVC [ml min−1 (100 mmHg)−1] | 379 ± 45a | 737 ± 85*a | 544 ± 62*†a | 782 ± 91*‡a | 839 ± 101*‡a | 744 ± 88*‡a |
Values are means ± SE. FBF, forearm blood flow; FVC, forearm vascular conductance; MVC, maximal voluntary contraction. *P < 0.01 vs. baseline; †P < 0.001 vs. exercise (control); ‡P < 0.001 vs. nadir; §P < 0.05 vs. inflation (steady state); aP < 0.01 vs. no drug trial; bP < 0.05 vs. no drug trial.